N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent-bearing acylation agent for the radioiodination of peptides and mAbs

Bioconjugate Chemistry

Volumn 14, Issue 2, 2003, Pages 331-341

  Shankar, Sriram ^a   Vaidyanathan, Ganesan ^a   Affleck, Donna ^a   Welsh, Phillip C ^a   Zalutsky, Michael R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLATION; AMINO ACIDS; CELL CULTURE; CELLS; TUMORS;

ACYLATIONS; FREE ACIDS; LABELING METHODS; LABELINGS; NEGATIVELY CHARGED; POSITIVELY CHARGED; POTENTIAL UTILITY; RADIOCHEMICAL YIELD; RADIOIODINATION; RADIOIODINE;

MONOCLONAL ANTIBODIES;

3 IODO 4 PHOSPHONOMETHYLBENZOIC ACID I 131; 4 DI TERT BUTYLPHOSPHONOMETHYL 3 TRIMETHYLSTANNYLBENZOIC ACID; BENZOIC ACID DERIVATIVE; IODINE 125; IODOTYROSINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY L8A4; N SUCCINIMIDYL 3 IODO 4 PHOSPHONOMETHYLBENZOATE I 131; N SUCCINIMIDYL 4 DI TERT BUTYLPHOSPHONOMETHYL 3 TRIMETHYLSTANNYLBENZOATE; PEPTIDE DERIVATIVE; RADIOLIGAND; UNCLASSIFIED DRUG;

ACYLATION; ANTIBODY LABELING; ARTICLE; CANCER RADIOTHERAPY; CONJUGATION; CONTROLLED STUDY; DRUG CLEARANCE; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; INTERNALIZATION; LYSOSOME; MOLECULAR WEIGHT; PH; PRECURSOR; RADIOACTIVITY; RADIOIODINATION;

EID: 0037345856     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc025636p     Document Type: Article

References (57)

1. Ali, S., Eary, J. F., Warren, S. D., Badger, C. C., and Krohn, K. A. (1988) Synthesis and radioiodination of tyramine cellobiose for labeling monoclonal antibodies. Nucl. Med. Biol. 15, 557-561.
2. Arano, Y., Mukai, T., Akizawa, H., Ueono, T., Montonari, H., Wakisaka, K., Kairiyama, C., and Yokoyama, A. (1995) Radiolabeled metabolites of proteins play a critical role in radioactivity elimination from the liver. Nucl. Med. Biol. 22, 555-564.
3. Baczko, K., Liu, W.-Q., Roques, B. P., and Garbay-Jaureguiberry, C. (1996) New synthesis of D, L.-Fmoc protected 4-phosphonomethylphenylalanine derivatives and their enzymatic resolution. Tetrahedron 52, 2021-2030.
4. Bhattacharya, A. K., and Thyagarajan, G. (1981) The Michaelis-Arbuzov Rearrangement. Chem. Rev. 81, 415-430.
5. Bray, H. G., Thorpe, W. V., and White, K. (1951) Kinetic studies of the metabolism of foreign organic compounds. I. Formation of benzoic acid from benzamide, toluene, benzyl alcohol, and benzaldehyde and its conjugation with glucoronic acid in the rabbit. Biochem. J. 48, 88-96.
6. Bridges, J. W., French, M. R., Smith, R. L., and Williams, R. T. (1970) The fate of benzoic acid in various species. Biochem. J. 118, 47-51.
7. Burke, T. R., Li, Z.-H., Bolen, J. B., and Marquez, V. E. (1991) Phosphonate-containing inhibitors of tyrosine-specific protein kinases. J. Med. Chem. 34, 1577-1581.
8. Crofts, P. C., and Kosolapoff, G. M. (1953) Preparation and determination of apparent dissociation constants of some alkylphoshphonic and dialkylphosphonic acids. J. Am. Chem. Soc. 75, 3379-3383.
9. de Jong, M., Valkema, R., Jamar, F., Kvols, L. K., Kwekkeboom, D. J., Breeman, W. A. P., Bakker, W. H., Smith, C., Pauwels, S., and Krenning, E. P. (2002) Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings. Sem. Nuc. Med. 32, 133-140.
10. Duncan, J. R., and Welch, M. J. (1993) Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins. J. Nuc. Med. 34, 1728-1738.
11. Engel, R. (1977) Phosphonates as analogues of natural phosphates. Chem. Rev. 77, 349-367.
12. Eummer, J. T., Gibbs, B. S., Zahn, T. J., Sebolt-Leopold, J. S., and Gibbs, R. A. (1999) Novel limonene phosphonate and farnesyl diphosphonate analogues: Design, synthesis, and evaluation as potential protein-farnesyl transferase inhibitors. Bioorg. Med. Chem. 7, 241-250.
13. Foulon, C. F., Reist, C. J., Bigner, D. D., and Zalutsky, M R. (2000) Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody. Cancer Res. 60, 4453-4460.
14. Foulon, C. F., Welsh, P. C., Bigner, D. D., and Zalutsky, M. R. (2001) Positively charged templates for labeling internalizing antibodies: Comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR. Nucl. Med. Biol. 28, 769-777.
15. a and log P values of some carboxylic and phosphonic acids: Synthesis and measurement. AAPS Pharm. Sci. 3, E10.
16. Geissler, F., Anderson, S. K., Venkatesan, P., and Press, O. (1992) Intracellular catabolism of radiolabeled anti-μ antibodies by malignant B-cells. Cancer Res. 52, 2907-2915.
17. 131I-labeled multivalent CC49 single-chain FVS. Clin. Cancer Res. 7, 175-184.
18. Govindan, S. V., Mattes, M. J., Stein, R., McBride, B. J., Karacay, H., Goldenberg, D. M., Hansen, H. J., and Griffiths G. L. (1999) Labeling of monoclonal antibodies with diethylenetriaminepentaacetic acid-appended radioiodinated peptides containing D-amino acids. Bioconjugate Chem. 10, 231-240.
19. Green, T. W., and Wuts, P. G. M. (1991) Protecting Groups in Organic Synthesis, 2nd ed., John Wiley & Sons, Inc., New York.
20. Gregus, Z., Fekete, T., Halaszi, E., and Klaassen, C. D. (1996) Lipoic acid impairs glycine conjugation of benzoic acid and renal excretion of benzoylglycine. Drug Metab. Dispos. 24, 682-688.
21. Hirom, P. C., Millburn, P., and Smith, R. L. (1976) Bile and urine as complementary pathways for the excretion of foreign compounds. Xenobiotica 6, 55-64.
22. Holtzman, E. (1989) Lysosomes, pp 95-100, Plenum Press, New York.
23. Hutt, A. J., and Caldwell, J. (1990) Amino Acid Conjugation. Conjugation Reactions in Drug Metabolism (G. J. Mulder, Ed.) pp 273-305, Taylor and Francis Ltd., London.
24. Illidge, T. M., and Brock, S. (2000) Radioimmunotherapy of cancer: Using monoclonal antibodies to target radiotherapy. Curr. Pharm. Des. 6, 1399-1418.
25. Jones-Wilson, T. M., Deal, K. A., Anderson, C. J., McCarthy, D. W., Kovacs, Z., Motekaitis, R. J., Sherry, A. D., Martell, A. E., and Welch, M. J. (1998) The in vivo behavior of Copper-64-labeled azamacrocyclic complexes. Nuc. Med. Biol. 25, 523-530.
26. 2α. J. Org. Chem. 52, 2958.
27. Kobayashi, H., Le, N., Kim, I.-S., Kim, M.-K., Pie, J.-E., Drumm, D., Paik, D. S., Waldmann, T. A., Paik, C. H., and Carasquillo, J. A. (1999) The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points. Cancer Res. 59, 422-430.
28. Lindmo, T., Boven, E., Cuttitta, F., Fedorko, J., and Bunn, P. A., Jr. (1984) Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods 72, 77-89.
29. Maack, T., Park, C. H., and Camargo, M. J. (1992) Filtration, transport, and metabolism of proteins. The Kidney: Physiology and Pathophysiology (D. W. Seldin, and G. Giebisch, Eds.) pp 3005-3038, New York: Raven Press.
30. 125I-tyramine, an improved residualizing label for studies on sites of catabolism of circulating proteins. J. Biol. Chem. 263, 14122-14127.
31. Moe, Jr., O. A. and Butler, L. (1983) The catalytic mechanism of bovine intestinal 5′-nucleotide phosphodiesterase. J. Biol. Chem. 258, 6941-6946.
32. Murray, J. L. (2000) Monoclonal antibody treatment of solid tumors: a coming of age. Sem. Oncol. 27, 64-70.
33. Nishikawa, R., Ji, X. D., Harmon, R. C., Lazar, C. S., Gill, G. N., Cavenee, W. K., and Huang, H. J. (1994) A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. U. S. A. 91, 7727-7731.
34. Pittman, R., Carew, T. E., Glass, C. K., Green, S. R., Taylor, C. A., Jr., and Attie, A. D. (1983) A radioiodinated, intracellularly trapped ligand for determining the sites of plasma protein degradation in vivo. Biochem. J. 212, 791-800.
35. Press, O. W., Shan, D., Howell-Clark, J., Eary, J., Appelbaum, F. R., Matthews, D., King, D. J., Haines, A. M., Hamann, L. Shochat, D., and Bernsetin, I. D. (1996) Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res. 56, 2123-2129.
36. Qian, Y., Vogt, A., Sebti, S. M., and Hamilton, A. D. (1996) Design and Synthesis of Non-Peptide Ras CAAX Mimetics as Potent Farnesyltransferase Inhibitors. J. Med. Chem. 39, 217.
37. Reist, C. J., Archer, G. E., Kurpad, S. N., Wikstrand, C. J., Vaidyanathan, G., Willingham, M. C., Moscatello, D. K., Wong, A. J., Bigner, D. D., and Zalutsky, M. R. (1995) Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: Use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. Cancer Res. 55, 4375-82.
38. Reist, C. J., Garg, P. K., Alston, K. L., Bigner, D. D., and Zalutsky, M. R. (1996) Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res. 56, 4970-4977.
39. Reist, C. J., Archer, G. E., Wikstrand, C. J., Bigner, D. D., and Zalutsky, M. R. (1997) Improved targeting of an antiepidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res. 57, 1510-1515.
40. 111In-diethylenetriaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo. Cancer Res. 55, 5714s-5720s.
41. Sneath, R. L., Jr., Wright, J. E., Soloway, A. H., O'Keefe, S. M., Dey, A. S., and Smolnycki, W. D. (1976) Protein-binding polyhedral boranes. 3. J. Med. Chem. 19 (11), 1290-1294.
42. Sun, X., Wuest, M., Weisman, G. R., Wong, E. H., Reed, D. P., Boswell, C. A., Motekaitis, R., Martell, A. E., Welch, M. J., and Anderson, C. J. (2002) Radiolabeling and in vivo behavior of Copper-64-labeled cross-bridged cyclam ligands. J. Med. Chem. 45, 469-477.
43. Thorpe, S. R., Baynes, J. W., and Chroneos, Z. C. (1993) The design and application of residualizing labels for studies of protein catabolism. FASEB J. 7, 399-405.
44. Vaidyanathan, G., and Zalutsky, M. R. (1990) Protein radiohalogenation: Observations on the design of N-succinimidyl ester acylation agents. Bioconjugate Chem. 1, 269-273.
45. 18F]fluorobenzoate and its application to the labeling of a monoclonal antibody fragment. Bioconjugate Chem. 5, 352-356.
46. Vaidyanathan, G., Affleck, D. J., and Zalutsky, M. R. (1997) Method for radioiodination of proteins using N-succinimidyl 3-hydroxy-4-iodobenzoate. Bioconjugate Chem. 8, 724-729.
47. Vaidyanathan, G., Zalutsky, M. R., and DeGrado, T. R. (1998) Iodopyridine-for-iodobenzene substitution for use with low molecular weight radiopharmaceuticals: application to m-iodobenzylguandine. Bioconjugate Chem. 9, 758-764.
48. 131I]SGMIB). Bioconjugate Chem. 12, 428-438.
49. Vaidyanathan, G., Affleck D. J., Bigner, D. D., and Zalutsky, M. R. (2002) Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate. Nucl. Med. Biol. 29, 1-11.
50. Van Wazer, J. R. (1958) Phosphorus and Its Compounds, pp 384-386, Volume 1, Interscience, New York.
51. Wan, S. H., and Riegelman, S. (1972) Renal contribution to overall metabolism of drugs. I. Conversion of benzoic acid to hippuric acid. J. Pharm. Sci. 61, 1278-1284.
52. Wigerinck, P., Kerremans, L., Claes, P., Snoeck, R., Maudgal, P., Declerq, E., and Herdewihn, P. (1993) Synthesis and antiviral activity of 5-thien-2-yl-2′-deoxyuridine analogues. J. Med. Chem. 36, 538-543.
53. Wikstrand, C. J., Hale, L. P., Batra, S. K., Hill, M. L., Humphrey, P. A., Kurpad, S. N., McLendon, R. E., Moscatello, D., Pegram, C. N., Reist, C. J., Traweek, T., Wong, A. J., Zalutsky, M. R., and Bigner, D. D. (1995) Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 55, 3140-3148.
54. Wikstrand, C. J., McLendon, R. E., Friedman, A. H., and Bigner, D. D. (1997) Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor EGFRvIII. Cancer Res. 57, 4130-4140.
55. Wikstrand, C. J., Reist, C. J., Archer, G. E., Zalutsky, M. R., and Bigner, D. D. (1998) The class III variant of the epidermal growth factor receptor (EGFRVIII): Characterization and utilization as an immunotherapeutic target. J. Neurol. Virol. 4, 148-158.
56. α-Fmoc-4-[di-(tert-butyl)-phosphonomethyl]phenylalanine from L-tyrosine. Tetrahedron Asymmetry 19, 3727-3734.
57. Zalutsky, M. R. (1997) Growth factor receptors as molecular targets for cancer diagnosis and therapy. Quart. J. Nucl. Med. 41, 71-78.